CM
CCCC icon

Caption Management’s C4 Therapeutics CCCC Stock Holding History

Caption Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$826K Buy
+176,800
New +$605K ﹤0.01% 1191
2022
Q3 		– Sell
-100,000
Closed -$754K – 1523
2022
Q2 		$754K Buy
+100,000
New +$880K 0.01% 972

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Caption Management's CCCC Position: Q2 2026 in Review

Caption Management opened a new position in C4 Therapeutics (CCCC) in Q2 2026: 35,000 shares worth $163K. The stake represents ﹤0.01% of the portfolio and ranks #1487 among its holdings. This is a return to the name: Caption Management previously reported a position in CCCC as recently as Q2 2022.

Caption Management first reported a position in CCCC in Q1 2022 and has held it in 3 quarters since. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Caption Management held 35,000 shares of C4 Therapeutics worth $163K as of Q2 2026.
  • C4 Therapeutics was a new Caption Management position in Q2 2026.
  • C4 Therapeutics made up ﹤0.01% of Caption Management's portfolio in Q2 2026, its #1487 holding.
  • Caption Management first reported a position in C4 Therapeutics in Q1 2022 and has held it in 3 quarters since.
  • 147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.